AbbVie, Inc. (ABBV)

Class Action & Lead Plaintiff Deadline: June 6, 2022

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie, Inc. ("AbbVie" or the “Company) (NYSE: ABBV) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, (the “Class Period”). Such investors are encouraged to join this case.  

 

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

 

The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis, As a result of the Defendants’ wrongful acts and omissions, and the significant decline in the market value of AbbVie’s securities, AbbVie investors have suffered significant damages.

 

A class action lawsuit has already been filed. You can review a copy of the Complaint and sign the certification form or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in AbbVie you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.